Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Level 5, Block E, Monash Medical Centre, 246 Clayton Road, Clayton, VIC, 3168, Australia.
Department of Rheumatology, Monash Health, Clayton, VIC, 3168, Australia.
Arthritis Res Ther. 2021 Jul 14;23(1):191. doi: 10.1186/s13075-021-02572-1.
We sought to examine the disease course of High Disease Activity Status (HDAS) patients and their different disease patterns in a real-world longitudinal cohort. Disease resolution till Lupus Low Disease Activity State (LLDAS) has been a general treatment goal, but there is limited information on this subset of patients who achieve this.
All consenting patients of the Monash Lupus Cohort who had at least 12 months of observation were included. HDAS was defined as SLEDAI-2K ≥ 10 ever, and HDAS episode as the period from the first HDAS clinic visit until attainment of LLDAS. We examined the associations of different HDAS patterns with the likelihood of damage accrual.
Of 342 SLE patients, 151 experienced HDAS at least once, accounting for 298 HDAS episodes. The majority of HDAS patients (76.2%) experienced Recurrent HDAS (> 1 HDAS visit), and a smaller subset (47.7%) had Persistent HDAS (consecutive HDAS visits for longer than 2 months). Recurrent or Persistent HDAS patients were younger at diagnosis and more likely to experience renal or serositis manifestations; persistent HDAS patients were also more likely to experience neurological manifestations. Baseline SLEDAI greater than 10 was associated with longer HDAS episodes. Recurrent and Persistent HDAS were both associated with an increased likelihood of damage accrual. The total duration of HDAS episode greater than 2 years and experiencing multiple HDAS episodes (≥4) was also associated with an increased likelihood of damage accrual (OR 1.80, 95% CI 1.08-2.97, p = 0.02, and OR 3.31, 95% CI 1.66-13.26, p = 0.01, respectively).
HDAS episodes have a highly variable course. Recurrent and Persistent HDAS, and longer duration of HDAS episodes, increased the risk of damage accrual. In addition to a major signifier of severity in SLE, its resolution to LLDAS can determine the subsequent outcome in SLE patients.
我们旨在通过真实世界的纵向队列研究,检查高疾病活动状态(HDAS)患者的疾病进程及其不同的疾病模式。达到狼疮低疾病活动状态(LLDAS)一直是治疗的一般目标,但对于达到这一目标的患者亚组,相关信息有限。
所有同意参加莫纳什狼疮队列研究且观察时间至少 12 个月的患者均被纳入研究。HDAS 的定义为 SLEDAI-2K 评分≥10 分,HDAS 发作定义为首次 HDAS 就诊至达到 LLDAS 的时间段。我们检查了不同 HDAS 模式与累积损伤风险的关系。
在 342 例 SLE 患者中,151 例患者至少经历过一次 HDAS,共发生 298 次 HDAS 发作。大多数 HDAS 患者(76.2%)经历过复发性 HDAS(>1 次 HDAS 就诊),一小部分(47.7%)为持续性 HDAS(连续 HDAS 就诊时间超过 2 个月)。复发性或持续性 HDAS 患者的诊断年龄较小,更可能出现肾脏或浆膜炎表现;持续性 HDAS 患者也更可能出现神经表现。基线 SLEDAI 评分>10 与 HDAS 发作时间较长有关。复发性和持续性 HDAS 均与累积损伤风险增加相关。HDAS 发作持续时间超过 2 年且发作次数≥4 也与累积损伤风险增加相关(OR 1.80,95%CI 1.08-2.97,p=0.02 和 OR 3.31,95%CI 1.66-13.26,p=0.01)。
HDAS 发作具有高度可变的病程。复发性和持续性 HDAS 以及 HDAS 发作持续时间较长,增加了累积损伤的风险。除了是 SLE 严重程度的主要指标外,其向 LLDAS 的缓解可以决定 SLE 患者的后续结局。